The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

Although gene therapy has shown prospects in treating triple-negative breast cancer, it is
insufficient to treat such a malignant tumor. Herein, nanoparticles (NPs)-embedded …

Selective degradation of the cyclin-dependent kinases 12 and 13 (CDK12/13) presents a
novel therapeutic opportunity for triple-negative breast cancer (TNBC), but there is still a lack …

Tumor metastasis and relapse mainly results in therapy failure and becomes a big challenge
in oncology. Immunogenic cell death (ICD) of tumors mediated immunotherapy (IT) is …

Immune checkpoint inhibitors (ICIs) have displayed potential efficacy in triple-negative
breast cancer (TNBC) treatment, while only a minority of patients benefit from ICI therapy …

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with
poor prognosis. TNBCs with high homologous recombination deficiency (HRD) scores …

Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the poorest
outcomes, and is associated with a high risk of relapse and metastasis. The treatment …

As it is closely associated with tumor proliferation, metastasis, and the immunosuppressive
microenvironment, the dysfunctional Hippo pathway has become an extremely attractive …

HDAC3 modulation shows promise for breast cancer, including triple-negative cases. Novel
pyrazino-hydrazide-based HDAC3 inhibitors were designed and synthesized. Lead …

Background Understanding the intricate signaling network involved in triple-negative breast
cancer (TNBC) represents a challenge for developing novel therapeutic approaches. Here …